FDA Background for Colon Cancer Endpoints Workshop

First Page		Document Content
Prodrugs Organofluorides Oxaliplatin Chemotherapy regimens Capecitabine Irinotecan Adjuvant therapy FOLFOX Levamisole Chemistry Medicine Pharmacology		FDA Background for Colon Cancer Endpoints Workshop Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 395,76 KB Share Document on Facebook

	AACL BIOFLUX Aquaculture, Aquarium, Conservation & Legislation International Journal of the Bioflux Society Effects of supplemented diets by levamisole and Echinacea purpurea extract on growth and DocID: 1rrYc - View Document
	Decoquinate Combined with Levamisole Reduce the Clinical Signs and Serum SAG 1, 5, 6 Antibodies in Horses with Suspected Equine Protozoal Myeloencephalitis Siobhan P. Ellison, DVM, PhD1 David S. Lindsay, PhD2 DocID: 1kMr0 - View Document
	PDF Document DocID: 1iN3X - View Document
	Anthelmintic drugs* Lindy Holden-Dye§ and Robert J. Walker, School of Biological Sciences, University of Southampton, Bassett Crescent East, Southampton SO16 7PX, UK Table of Contents DocID: 1gh6R - View Document
	Samenvatting Goedgekeurd Eindverslag Versie: april 2010 Titel: Efficacy and safety of levamisole treatment in children with steroid sensitive nephrotic syndrome DocID: 1f8L1 - View Document